The role of novel biomarker HE4 in the follow-up of ovarian cancer

The role of novel biomarker HE4 in the follow-up of ovarian cancer - The role of novel biomarker HE4 in the follow-up of ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038016

Enrollment

Registered

2019-09-17

Start date

2019-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer, follopian tube cancer, primary peritoneal cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ovarian cancer, follopian tube cancer, or primary peritoneal cancer. 2. clinical stage III or IV. 3. CA125 (U/mL): 35 or more. 4. HE4 (pmol/L): 70 or more (premenopause), 140 or more (postmenopause). 5. no therapy

Exclusion criteria

Exclusion criteria: 1. other malignancy 2. Patients judged inappropriate by the doctor

Design outcomes

Primary

Measure	Time frame
To search for the optimal index for detection of recurrence by the increasing of HE4 values.	—

Secondary

Measure	Time frame
1. To compare the recurrence detection time in the optimal index of HE4 with the recurrence diagnosis time by image detection. 2. Search for factors that affect recurrence, therapeutic efficacy, and prognosis.	—

Countries

Japan

Contacts

Public ContactYuji Takei

Jichi Medical University Department of Obstetrics and Gynecology

ytakei@jichi.ac.jp0285-58-7376

Outcome results